BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced the first sale of the IOPtiMate system to a medical center located in Peru.
The IOPtiMate system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.
Up until recently, the IOPtiMate system has been marketed primarily to leading physicians and medical centers in Asia and Europe.
These marketing efforts have resulted in recent first sales of the IOPtiMate system in Hong Kong, Poland, Hungary and Romania.
Moving forward, and in keeping with the Company’s focus on markets with unmet needs for better solutions to treat glaucoma, BioLight is now also negotiating additional distribution agreements in South and Central America.
BioLight invests in, manages and commercializes biomedical innovations grouped around defined medical conditions – ophthalmology and cancer diagnostics.